Axsome Therapeutics, Inc. (AXSM)
$168.35-1.02%Close
SELLCRISIS · day 13
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8.7B
- Beta
- 0.60
- P/E (TTM)
- -46.49
- Short % float
- 7.59%
- Days to cover
- 4.4
- SI change
- +5.3%
- 1W
- -6.08%
- 1M
- -20.26%
- vs SPY 1W
- -7.24%
- vs SPY 1M
- -23.25%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$14.3BRECOVERYQ 17$142.44+0.84%
- JAZZSELLJazz Pharmaceuticals plc$13.7BBEARQ 24$218.42-1.81%
- PRAXSELLPraxis Precision Medicines, Inc.$7.2BCRISISQ 11$259.86-1.40%
- DFTXSELLDefinium Therapeutics, Inc.$4.9BBEARQ 26$36.90+7.96%
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.44+0.77%
- DNLISELLDenali Therapeutics Inc.$3.1BCRISISQ 8$19.45+4.18%
- SUPNBUYSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.67+1.26%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 25$30.65+2.68%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 23
- VALUE
- 7
- GROWTH
- 6
- GARP
- 57
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-153.4%
REV YoY-
ROE-255.6%
EPS YoY-
ROA-25.2%
GROSS93
OP-24
NET-25
[VALUATION]
P/E TTM-46.49
P/E FWD43.73
SECTOR PE20.47
INDUSTRY PE13.95
P/B107.78
P/FCF-
EV/EBITDA-49.34
EV/EBIT-
PEG0.51
FCF YIELD-
RISK
INT COV-
D/E263.14
ALTMAN Z-
CURR RATIO1.43
ND/EBITDA-
BETA0.60
